Do CBDa and CBGa help prevent COVID infection? An interesting study emerging from OSU suggests this is possible. Researchers found that both CBDa and CBGa bind to spike proteins on the virus which blocks a critical step in the infection process. CBGa and CBDa are the acidic precursors to CBD and CBG. It is important to note that the vast majority of formulated CBD products do not contain the acidic versions. We have specific extraction processes that maintain the acidic versions.

Specifically, our CBDa capsules are made with CO2 extraction techniques to preserve the acid cannabinoid. CBGa is even more challenging to find in formulated products. Our most popular is the concentrated collection of CBGa-rich trichomes. Customers consume this blend raw by adding it to tinctures, oils, or drinks. Our CBG white kief tested at 44% CBGa by weight. 1 gram will contain 440 mg of CBGa!  We have also had feedback from users who are pressing their own CBGa pills and CBGa capsules.

If you wish to make your own CBDa capsules or pills from CBDa oil or kief, there are many home capsule kits for less than $100.  Instructions forthcoming shortly.  Watch this blog for details.

About the study: 

After launching their Global Hemp Innovation Center in 2018, Oregon State University has fast-tracked its research initiatives. Some of these research initiatives include testing Hemp’s Antimicrobial Activity and whether hemp biomass could be used as an animal feed ingredient. On Monday, January 10th, Oregon State’s Richard van Breemen along with Oregon State’s College of Pharmacy, Linus Pauling Institute, and scientists from OSHU published a research paper that demonstrated in vitro that certain cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants. They discovered that two (CBDa & CBGa) cannabinoid acids bind to the SARS-CoV-2 spike protein. This spike protein is the same target that current vaccines and antibodies go after, which shows the potential in disrupting infection and disease progression.

This is not the first time that CBD and other cannabinoids have been used in SARS research, but it could provide insight into why some of the other studies have not been as widely considered successful. A Brazilian study completed in January 2021 showed that a daily administration of 300 mg CBD for 14 days failed to alter the clinical evolution of COVID-19. Israeli research firms Eybna and CannaSoul are teaming up using an NT-VRL compound based on a 2002 SARS study that found terpenes to be effective antiviral agents. They even combined their NT-VRL compound with CBD to find that it was more than twice as effective as just CBD or Dexamethasone (a common corticosteroids treatment for inflammation) in treating cytokine storms.

Utilizing affinity selection mass spectrometry (simply put, incubating the target with a blend of potential ligands or things that might bind to it), Oregon State’s own Richard van Breemen said,

“We identified several cannabinoid ligands and ranked them by affinity to the spike protein. The two cannabinoids with the highest affinities for the spike protein were CBDA and CBGA, and they were confirmed to block infection. These compounds can be taken orally and have a long history of safe use in humans. They have the potential to prevent as well as treat infection by SARS-CoV-2. CBDA and CBGA are produced by the hemp plant as precursors to CBD and CBG, which are familiar to many consumers. However, they are different from the acids and are not contained in hemp products.”

Oregon State’s Richard van Breeman also mentioned that early research showed that licochalcone A, found in Licorice, could also bind to the spike protein, but further research and funding would be needed to test it on a live sample.

Horn Creek is proud to cheer on our friends over at Oregon State in discovering more abstract ways to utilize Hemp. We understand that this is a building block study and not a smoking gun, but local excitement is large and we all love supporting our local community. A tip of our farmer’s cap is deserved, well done.